Letter – To SMH … Hepatitis and Liver Cancer: A National Strategy for Prevention & Control of Hepatitis B and C

Dear Mr. Tibbs:

Thanks for the information. We already know the linkage between chronic hepatitis B and chronic hepatitis C and the liver cancer. HepC Herba™ has been shown to help restore the liver function, reverse liver cirrhosis possibly through liver regeneration by itself while modulate the chronic inflammation of the liver and stop the progression of the chronic liver inflammation disease. I expect HepC Herba™ would help prevent liver cancer by calming down the chronic liver inflammation which can lead to deadly liver cirrhosis and liver cancer.

However, the presence of the hepatitis B virus or hepatitis C virus alone in the liver, for those who are the carriers, can still lead to liver cancer. HepC Herba™ has been shown to reduce the viral load in people with chronic hepatitis C. We still do not know how low the viral load should be so the presence of the virus would not lead to liver cancer. A retroactive research is needed to review the viral load of chronic hepatitis C patients who had developed liver cancer as compared to those who had not. We need to find or encourage a scientist to apply for a NIH grant to do this.

For those carriers, they still need to be monitored periodically, say every 4 to 6 months, for potential development of chronic hepatitis or liver cancer. This can be done throught routine blood test for liver enzymes panel, including AST (SGOT), ALT (SGPT), alkaline phosphatase, and alpha-feto protein.

You may want to put my comment in your website in FAQ section.


Shie-Ming Hwang, Ph.D.

Leave a Reply

Your email address will not be published. Required fields are marked *